The European Brain Council (EBC), in collaboration with the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Swedish Brain Foundation (SBF) and the Swedish Association of the Pharmaceutical Industry (LIF), will explore the ways we can rethink the Alzheimer’s care pathway, particularly in the Swedish healthcare ;

The virtual event follows the launch of the Rethinking Alzheimer’s Disease White Paper: Detection & Diagnosis, looking at how to detect and diagnose the disease at an earlier stage (at mild cognitive impairment – MCI  – stage) and what new care pathways would need to be implemented to reach out to patients at that stage.

Furthermore, with disease modifying treatments targeting patients with MCI potentially coming to market in the near future, it is important to see how prepared healthcare systems are to provide these new ; 

The programme will feature keynote speeches on daily life living with Alzheimer’s disease and how we can rethink the Alzheimer’s care pathway, a panel discussion featuring key opinion leaders and experts involved in the Rethinking Alzheimer’s disease project, and much ;Follow the EBC social media channels (Twitter, LinkedIn) and dedicated newsletter for all the latest updates – more information coming soon!